There was a notable gap in effectiveness between metered-dose and dry-powder formulations of single-inhaler triple therapy for chronic obstructive pulmonary disease (COPD), according to real-world ...
Changing patients from an inhaled corticosteroid (ICS)/long-acting β agonist (LABA) inhaler and long-acting muscarinic agonist (LAMA) inhaler to a LAMA/LABA inhaler and a separate ICS inhaler did not ...
Please provide your email address to receive an email when new articles are posted on . Perioperative combination therapy using a long-acting muscarinic antagonist and long-acting beta agonist may be ...
Triple fixed-dose regimens of an inhaled glucocorticoid, a long-acting muscarinic antagonist (LAMA), and a long-acting β 2-agonist (LABA) for chronic obstructive pulmonary disease (COPD) have been ...
Please provide your email address to receive an email when new articles are posted on . This analysis spanned from 2016 to 2022. Nearly 50% of patients were initially prescribed LABA/inhaled ...
AeroRx Therapeutics, Inc., a clinical-stage biopharmaceutical company developing proprietary nebulized combination therapies for chronic respiratory diseases, today announced the closing of a $21 ...
An overview of the medication classes available for the treatment of chronic obstructive pulmonary disease and recommendations for how to utilize and in whom. Transcript: Neil B. Minkoff, MD: Let’s ...
LA JOLLA, Calif., October 07, 2025--(BUSINESS WIRE)--AeroRx Therapeutics, Inc., a clinical-stage biopharmaceutical company developing proprietary nebulized combination therapies for chronic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback